Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
Details
Account Type
CFD Trading: MetaTrader 5
CFD Trading: MetaTrader 5
Investing: Web
Commission
0.1%
Trading schedule (UTC)
Open NowClosed NowCloses onOpening on
at
-
This shows the opening hours in your local time zone
(UTC)
Open an account and start investing with Metadoro now. Invite friends and get rewarded for their active trading. You can learn more about the affiliate program in your personal account.
Thank you for visiting metadoro.com. This website is managed by RHC Investments, which is authorised and regulated as an Investment Dealer by the Financial Services Commission of Mauritius with License number C115015381. Mauritius is not part of the European regulatory framework and is not in scope of (among others) the Markets in Financial Instruments Directive (MiFID) II.
By continuing you confirm that the decision is made independently and at your own exclusive initiative and that no solicitation or recommendation has been made by RHC Investments.
Create a NewsletterCreate a Newsletter
Customize your subscriptions the way you want!
Analytics
Get notified upon new posts
Select category
Price alerts
Discover timely market up-and-downs, pumps, etc.
Select category
Alert method
All categoriescategoriesAll instrumentsinstrumentssearchNothing found